Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-specific T cells in advanced solid tumors
NCT06431529Phase 1Recruiting
- Sponsor
- Jiangsu Longwei Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Jiangsu Longwei Pharmaceutical. Primary endpoint: Safety of tumor neoantigen specific T cells at 2 years. Started Apr 2024; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06431529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431529.